PATENT CLAIM ANALYSIS

Application Number: 16027629
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["424", "093710"]

Abstract:
Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

Claim (Index 27):
The isolated genetically-modified human T cell of  claim 26 , wherein the integration into the TCR alpha constant chain region is at a position within the sequence: (SEQ ID NO: 60) TGAGGTCTATGGACTTCAAGAGCAACAGTGCTGTGGCCTGGAGCAACAA.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 95.0
- Lexical Diversity: 1.49351
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15659792', '14403937', '14018021', '15711289', '15864984']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8526439579090155
- 35 USC 102 Novelty (BERT): 0.6413452006091049
- Combined Prediction Score: 0.8315140821790244
- Mean Citation Score: 730.8266540000003
- Max Citation Score: 856.20294
- Similarity Product: 547.2723411217331

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test